Combined data from RISC (n=3,024) and San Raffaele dataset (n=1,067)

Slides:



Advertisements
Similar presentations
1 Renal Pelvis, Ureter, Bladder and Other Urinary.
Advertisements

The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.
AUDIT OF COMPLIANCE WITH NHSCSP GUIDELINES REQUIRING MDT REVIEW OF ALL CERVICAL CANCER PATIENTS Dr. M Bhattacharjee Dr. A Mutton Dr. S Nagarajan.
The long term outcome of high risk non-muscle invasive bladder cancer. F Thomas, N Rubin, J Goepel, D Rosario, MF Abbod, JWF Catto. Academic unit of Urology,
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Urinary Diversion: Does RARC learning curve affect diversion choice in urothelial carcinoma PG O’Malley 1, B Al Hussein Al Awamlh 1, DP Nguyen 1, BM Faltas.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Variation in Outpatient Antibiotic use for Acute Respiratory Infections in the Veteran Population. Final Figures 1, 2, 3, 4, 5, 6.
 T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
*Be brief, yet thorough enough to allow recoding of the data fields from the text only! * Use accepted abbreviations from Abstractor’s Manual Appendix.
Clinical History Patient presents with a palpable upper abdominal mass Patient states possible clinical history of abdominal hernia.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
K Nouso, K Miyahara, D Uchida, K Kuwaki, N Izumi, M Omata, T Ichida, M Kudo, Y Ku, N Kokudo, M Sakamoto, O Nakashima, T Takayama, O Matsui, Y Matsuyama,
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND URETER
Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?
Volume 71, Issue 2, Pages (February 2017)
Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,
Copyright © 2014 American Medical Association. All rights reserved.
Cervical Screening Programme, England, : Graphs
Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma  Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
Fig. 1. Immunostaining for AhR in non-neoplastic urothelium ( A ), superficial UC ( B ) and invasive UC ( C ). ( A ) Weak cytoplasmic staining in the.
Prognosis of younger patients in non-small cell lung cancer
LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.
Volume 57, Issue 6, Pages (June 2010)
2018/03/18 外科年會 Oral Presentation
Building better therapy for children with acute lymphoblastic leukemia
Guan-Lin Huang, Luo-Hao Lun, Yen-Ta Chen, Yuan Tso Cheng
Tissue Acquisition and Reflex Testing How do we Prioritize?
Prospective evaluation of preoperative
The IASLC Lung Cancer Database
Nitsan Maharshak, Scott E. Plevy 
Volume 72, Issue 5, Pages (November 2017)
Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic.
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Volume 61, Issue 5, Pages (May 2012)
Volume 69, Issue 5, Pages (May 2016)
NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract  Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima,
Tissue acquisition and reflex testing. How do we prioritize?
Figure 6 Common signalling mechanisms, pathways,
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract  Ji Yun Lee, Kyung Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong.
Volume 66, Issue 6, Pages (December 2014)
Volume 67, Issue 6, Pages (June 2015)
Volume 53, Issue 1, Pages (January 2008)
Role of cytokeratins in the diagnosis and prognosis of the bladder cancer Giorgi Adeishvili MD Multiprofile clinic Consilium Medulla.
Neutrophil / Lymphocyte ratio (NLR)
4155 primary hepatocellular carcinoma with known diagnosis month/year
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
From NICE CG 104, 2010 Table 1 Terms used in this guideline
Patients who have received chemotherapy (n=60)
Volume 5, Issue 6, Pages e3 (December 2017)
Disease-specific survival
* *.
Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry  Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,
Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute  Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.
Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.
Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,
Histological Scoring for Small Lung Adenocarcinomas 2 cm or Less in Diameter: A Reliable Prognostic Indicator  Akiko Miyagi Maeshima, MD, Naobumi Tochigi,
Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.
Supplementary Figure S1
Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.
Neal S Goldstein, MD  The Annals of Thoracic Surgery 
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.
Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer  Caroline.
Figure 12a Pitfalls in N staging at CT and PET
Presentation transcript:

Combined data from RISC (n=3,024) and San Raffaele dataset (n=1,067) Supplementary Figure 1 Study flow chart, with reasons and counts for patient exclusions. RC = radical cystectomy; RISC = Retrospective International Study of Invasive/Advanced Cancer of the Urothelium; UC = urothelial carcinoma. Combined data from RISC (n=3,024) and San Raffaele dataset (n=1,067) n=1,480 excluded for clinical N1-3 stage, and 851 for clinical M1 stage n=132 upper-tract or urethral primary tumor n=434 did not undergo RC n=1,194 selected patients n=78 with predominant non-UC histology n=166 missing key survival data n=950 patients in the final data analyses